^
Association details:
Biomarker:No biomarker
Cancer:Follicular Lymphoma
Drug:Rituxan Hycela (rituximab/hyaluronidase) (CD20 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with…Follicular Lymphoma (FL)… Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as singleagent maintenance therapy
Secondary therapy:
Chemotherapy